{"protocolSection":{"identificationModule":{"nctId":"NCT04412850","orgStudyIdInfo":{"id":"huda01"},"organization":{"fullName":"Dow University of Health Sciences","class":"OTHER"},"briefTitle":"Intravenous Magnesium Sulphate in Acute Ischemic Stroke","officialTitle":"Role of Intravenous Magnesium Sulphate in Improving Clinical Outcome in Patients Suffering From Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2020-06","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-12-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2021-06-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2021-08-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-05-11","studyFirstSubmitQcDate":"2020-06-01","studyFirstPostDateStruct":{"date":"2020-06-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-06-01","lastUpdatePostDateStruct":{"date":"2020-06-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Huda Naim","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Dow University of Health Sciences"},"leadSponsor":{"name":"Dow University of Health Sciences","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Magnesium has a neuroprotective role so the investigators aim to evaluate the role of intravenous magnesium sulphate in improving the clinical outcomes as assessed by the NIH Stroke Scale (NIHSS) in patients with acute ischemic stroke."},"conditionsModule":{"conditions":["Stroke","Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":44,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Control group","type":"EXPERIMENTAL","description":"Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.","interventionNames":["Drug: Magnesium Sulfate"]},{"label":"placebo group","type":"PLACEBO_COMPARATOR","description":"Normal Saline in equal volume as the control group.","interventionNames":["Drug: Magnesium Sulfate"]}],"interventions":[{"type":"DRUG","name":"Magnesium Sulfate","description":"Magnesium and placebo (Normal Saline) will be prepared as solutions of identical volume and appearance. All patients will be randomized and blind to treatment.\n\nAll patients will have pretreatment Electrogram (ECG), serum biochemistry and serum Magnesium levels. Serum Magnesium levels will also be measured at 48 hours. Blood pressure, heart rate, respiratory rate and serious adverse events will be monitored at baseline, 15 minutes, and 12, 24 and 48 hours after infusion. Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form.\n\nFollow-up visits will be conducted by the same investigators, and repeated scores on the NIH Stroke Scale will be obtained at 24 hours, 48 hours post admission and on the day of discharge.","armGroupLabels":["Control group","placebo group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Improvement In Clinical Outcome As Measured By The improvement in NIH Stroke Scale After Infusion Of Magnesium Sulphate In Patients Suffering From Acute Ischemic Stroke.","timeFrame":"7 days"}],"secondaryOutcomes":[{"measure":"adverse effects","timeFrame":"7 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults with a confirmed diagnosis of ischemic stroke on neurological examination and CT scan findings aged between 45 -95 years of age of either gender.\n* Adults presenting within a stroke onset of 24 hours.\n\nExclusion Criteria:\n\n* Patients with confirmed diagnosis other than ischemic stroke (evidence of Intracranial bleed or space occupying lesion)\n\n  * Subjects with systolic blood pressure less than 90mmHg\n  * Presence of Bundle Branch block or atrioventricular block.\n  * Serum Creatinine \\> 3mg/dl\n  * Respiratory failure (O2 saturation \\<90% or Respiratory Rate \\>24 or \\<12)\n  * Pregnancy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","maximumAge":"95 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Huda Naim, MBBS","role":"CONTACT","phone":"03333656270","email":"huda_naim@live.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000008278","term":"Magnesium Sulfate"}],"ancestors":[{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000777","term":"Anesthetics"},{"id":"D000002492","term":"Central Nervous System Depressants"},{"id":"D000000889","term":"Anti-Arrhythmia Agents"},{"id":"D000000927","term":"Anticonvulsants"},{"id":"D000002121","term":"Calcium Channel Blockers"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000077264","term":"Calcium-Regulating Hormones and Agents"},{"id":"D000015149","term":"Tocolytic Agents"},{"id":"D000012102","term":"Reproductive Control Agents"}],"browseLeaves":[{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M10960","name":"Magnesium Sulfate","asFound":"Increasing","relevance":"HIGH"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M3797","name":"Anesthetics","relevance":"LOW"},{"id":"M3903","name":"Anti-Arrhythmia Agents","relevance":"LOW"},{"id":"M3936","name":"Anticonvulsants","relevance":"LOW"},{"id":"M5071","name":"Calcium","relevance":"LOW"},{"id":"M5088","name":"Calcium, Dietary","relevance":"LOW"},{"id":"M5074","name":"Calcium Channel Blockers","relevance":"LOW"},{"id":"M9479","name":"Hormones","relevance":"LOW"},{"id":"M17559","name":"Tocolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnArAg","name":"Anti-Arrhythmia Agents"},{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"AntiConv","name":"Anticonvulsants"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"Repr","name":"Reproductive Control Agents"},{"abbrev":"BDCA","name":"Bone Density Conservation Agents"}]}},"hasResults":false}